Director at Versigent (VGNT) receives 5,168-share equity grant

Rhea-AI Filing Summary

Versigent PLC director Brad M. Cerepak received a grant of 5,168 Ordinary Shares as equity compensation. The shares were acquired on a non-cash basis at a reported price of $0.0000 per share. Following this award, he directly holds 5,168 Ordinary Shares, with no derivative positions reported.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider Cerepak Brad M

Role null

Type	Security	Shares	Price	Value
Grant/Award	Ordinary Shares	5,168	$0.00	--

Holdings After Transaction: Ordinary Shares — 5,168 shares (Direct, null)

Footnotes (1)

Key Figures

Equity grant size: 5,168 shares Grant price per share: $0.0000 per share Total holdings after grant: 5,168 shares +2 more

5 metrics

Equity grant size 5,168 shares Ordinary Shares granted to director on 2026-04-22

Grant price per share $0.0000 per share Reported transaction price for awarded Ordinary Shares

Total holdings after grant 5,168 shares Non-derivative Ordinary Shares directly owned after transaction

Transaction code A Classified as “Grant, award, or other acquisition”

Transaction date 2026-04-22 Date of Ordinary Share grant reported on Form 4

Key Terms

Grant, award, or other acquisition, Ordinary Shares, non-derivative, Form 4

4 terms

Grant, award, or other acquisition financial

"transaction_code_description: "Grant, award, or other acquisition""

Ordinary Shares financial

"security_title: "Ordinary Shares" for the reported transaction"

Ordinary shares are a type of ownership stake in a company, giving shareholders a right to participate in the company’s profits and decision-making through voting. They are similar to owning a piece of a business, and their value can rise or fall based on the company's performance. Investors buy ordinary shares to potentially earn dividends and benefit from the company's growth over time.

non-derivative financial

"transaction_type: "non-derivative" describing the equity grant"

Form 4 regulatory

"INSIDER FILING DATA (Form 4): { "issuerName": "Versigent PLC""

Form 4 is a official document that company insiders, such as executives or major shareholders, file with regulators whenever they buy or sell company shares. It provides transparency about how those with inside knowledge are trading, helping investors see if insiders are confident in the company's prospects or may be selling for personal reasons. This information can influence investor decisions by revealing insiders' perspectives on the company's value.

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Cerepak Brad M

(Last) (First) (Middle)

SPITALSTRASSE 5,

(Street)

SCHAFFHAUSEN SWITZERLAND 8200

(City) (State) (Zip)

SWITZERLAND

(Country)

2. Issuer Name and Ticker or Trading Symbol
Versigent PLC [ VGNT ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
04/22/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Ordinary Shares	04/22/2026		A		5,168	A	$0	5,168	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

	/s/ Janis Acosta, Attorney-in-fact for Brad Cerepak	04/24/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What insider transaction did Versigent (VGNT) report for Brad M. Cerepak?

Versigent reported that director Brad M. Cerepak received a grant of 5,168 Ordinary Shares. The acquisition is classified as a grant, award, or other acquisition, reflecting equity-based compensation rather than an open-market purchase, and is recorded as a direct ownership position.

How many Versigent (VGNT) shares does Brad M. Cerepak hold after this Form 4?

After the reported transaction, Brad M. Cerepak directly holds 5,168 Ordinary Shares of Versigent. The entire reported position comes from this single equity grant, and no additional non-derivative or derivative holdings are listed in the filing as of the transaction date provided.

Was cash paid for the 5,168 Versigent (VGNT) shares granted to Brad M. Cerepak?

No cash was paid for these shares; the filing shows a transaction price per share of $0.0000. This indicates the 5,168 Ordinary Shares were received as a grant or award, consistent with equity compensation rather than a market purchase involving cash consideration.

Is the Brad M. Cerepak Form 4 for Versigent (VGNT) an open-market buy or a grant?

The transaction is a grant, not an open-market buy. It is coded as an “A” transaction, with the description “Grant, award, or other acquisition,” and shows a zero dollar price per share, indicating compensation-related share issuance instead of a market transaction.

Does Brad M. Cerepak have any Versigent (VGNT) derivative positions reported in this filing?

No derivative positions are reported for Brad M. Cerepak in this Form 4. The filing’s derivative summary is empty, and all disclosed activity involves non-derivative Ordinary Shares, limited to the single 5,168-share grant reported on the stated transaction date.